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Uptake and efflux of two anthracyclines, idarubicin (IDA) and daunorubicin (DNR),
was studied in childhood acute leukemia samples. A comparison of IDA and DNR
transport phenomena in relation to drug cytotoxicity and expression of P-glycoprotein
(PGP) was made. Intracellular content of IDA/DNR was determined by flow
cytometry using the fluorescent properties of the drugs. In vitro drug cytotoxicity was
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measured by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT)
assay. PGP expression was analysed by flow cytometry. The uptake and efflux rates
were non-significantly higher for IDA than DNR. There were no differences between
three types of leukemia with respect to drug content during accumulation and reten-
tion. After correction for the cell volume, intracellular concentration of both drugs in
each moment of uptake and efflux was significantly lower in relapsed ALL and AML
samples in comparison with initial ALL cells. Efflux, but not uptake, of both drugs was
inversely correlated with PGP expression and IDA, but not DNR, cytotoxicity. The
cytotoxicity was correlated with drug accumulation for both drugs and with drug re-
tention for IDA. In conclusion, it seems that (1) intracellular content was related to the
lipophilic properties of the drugs rather than to the type of leukemia, (2) decreased
intracellular concentration of both drugs might have an impact on compromised ther-
apy results in AML and relapsed ALL children, (3) IDA presents higher cytotoxicity,
which possibly might be decreased by the presence of PGP. These results might have a
practical impact on the rational design of new chemotherapy protocols.
Leukemia is the most common childhood
malignancy. Acute lymphoblastic leukemia
(ALL) is the predominant form (85%) and
acute myeloblastic leukemia (AML) is a rela-
tively uncommon disease (10–15%). With cur-
rent protocols, 70–80% of children with ALL,
and only 30–50% with AML can be cured [1].
Drug resistance is related to relapse of leuke-
mia, but the underlying mechanisms are still
poorly understood. Anthracyclines (Fig. 1) are
among the drugs used in both types of acute
leukemia. Idarubicin (IDA) is a relatively new
antitumor anthracycline drug and is thought
to be more active and less cardiotoxic than
daunorubicin (DNR) [2]. Resistance to
anthracyclines may compromise therapy re-
sults. The resistance may be caused by re-
duced intracellular drug levels due to its se-
questration by multidrug resistance proteins
or detoxification by glutathione and its
S-transferases, a reduced amount of active
intracellular drug target, such as topoiso-
merase II, and resistance to apoptosis or its
protein disregulation [3]. Anthracyclines en-
ter the cell by passive diffusion, most likely in
an unchanged form [4, 5]. So far most infor-
mation about anthracycline resistance was ob-
tained from in vitro studies on tumor cell
lines. There is only one study on childhood
acute leukemia, reporting a relationship be-
tween intracellular DNR concentration, ex-
pression of resistance proteins and DNR cyto-
toxicity in ALL [6]. It shows that intracellular
DNR concentration and the expression of
Lung-Resistance-Protein (MVP/LRP), but not
P-glycoprotein (PGP), may contribute to DNR
resistance in childhood ALL. So far there are
no reports available showing whether intra-
cellular IDA content is related to cellular drug
resistance and multi-drug resistance proteins
expression in childhood leukemia. Moreover,
it is unknown what differences in intracellular
anthracycline levels occur between ALL and
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Figure 1. Chemical structure of anthracyclines.
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AML, and if they might contribute to differ-
ences in drug resistance.
The scope of this study is an analysis of up-
take and efflux rates as well as intracellular
IDA content and concentration in childhood
acute leukemia. Another objective is a com-
parison of IDA and DNR transport phenom-
ena in relation to cytotoxicity and expression
of PGP.
MATERIALS AND METHODS
Leukemic cell samples. Samples of leuke-
mic cells of 61 children aged 0.5–18 yrs (me-
dian 8 yrs), including 34 with ALL de novo
(iALL, group A), 13 relapsed ALL (rALL,
group B) and 14 de novo AML (iAML, group
C), were analysed. Only fresh peripheral blood
(PB) or bone marrow (BM) samples taken at
the moment of diagnosis or relapse were ana-
lysed. Cells were isolated by centrifugation on
Ficoll gradient at 480  g for 20 min at room
temperature, washed twice and resuspended
in RPMI-1640 (Sigma, St. Louis, MO, U.S.A.)
with 20% fetal calf serum (FCS, Gibco BRL,
Life Technologies, Germany), 2 mM L-glu-
tamine, 5 g/ml insulin, 5 g/ml transferrin,
5 ng/ml sodium selenite (all from Sigma) and
antibiotics. All samples presented at least 95%
cell viability (determined morphologically by
trypan blue exclusion assay) and contained at
least 80% of leukemic cells, as calculated on
cytospin slides stained with the May-Grun-
wald-Giemsa method. The concentration of
leukemic cells was adjusted to 2  106/ml.
Drugs. Daunorubicin (Cerubidine; Rhone
Poulenc Rorer, Amstelveen, The Nether-
lands) and idarubicin (Zavedos; Pharmacia
Farmitalia Oncology, Italy) were used for the
study.
Drug accumulation and retention. Leuke-
mic cells at a concentration of 0.5  106
cells/ml were incubated with 10 g/ml of re-
spective drug in humidified air containing 5%
CO2 at 37C. Samples of cells were analysed in
1 h intervals. Accumulation of DNR/IDA was
determined at certain time points during con-
tinuous exposure to DNR/IDA. To study the
retention, cells were first loaded with
10 g/ml DNR/IDA for 1 h at 37C. In order
to start the efflux, cells were washed in
ice-cold phosphate-buffered saline (PBS) and
resuspended in a pre-warmed drug-free me-
dium. The retained amount of DNR/IDA was
determined at several time points, including
the start of efflux (t = 0). Each aliquot (100 l)
was washed immediately in ice-cold PBS and
then intracellular DNR/IDA fluorescence
(FL) was measured by flow cytometry (Coul-
ter EPICS XL3, Miami, FL, U.S.A.). The con-
tent of intracellular IDA/DNR was deter-
mined by flow cytometry using the fluores-
cent properties of the drugs. DNR/IDA was
excitated by an argon laser at 488 nm and the
fluorescence signal was collected through a
515–535 nm (FL1 height), 565–585 nm (FL2
height) and 610–630 nm (FL3 height)
bandpass filter set. The strongest emission
was observed for the FL2 filter for IDA and
FL3 filter for DNR. The instrument settings
for FL2 and FL3 heights, forward scatter
(FSC) and sideward scatter (SSC) were kept
constant between two runs of the flow
cytometer. The data were analysed using the
SYSTEM II version 3.0 software (Beckman
Coulter, Miami, FL, U.S.A.). Viable leukemic
cells were gated based on FSC and SSC char-
acteristics. The percentage of gated cells cor-
responded well with the percentage of viable
cells determined morphologically by trypan
blue exclusion. The intracellular drug content
was determined by the mean fluorescence in-
tensity of gated leukemic cells, and was ex-
pressed in arbitrary units (AU) on a log-scale.
The FSC of gated leukemic cells was used as a
relative measure of cell volume (FSC3) in this
study. The intracellular drug concentration
(cDNR/cIDA) was obtained by dividing the
intracellular DNR/IDA content by the relative
cell volume (AU/FSC3) [6]. The percentage of
drug retention was calculated by dividing the
drug-fluorescence retained in the cell after a
period of efflux by the drug-fluorescence pres-
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ent at the start of efflux (t = 0)  100%. The
intracellular drug content, intracellular drug
concentration or percentage of drug retention
did not differ between bone marrow and pe-
ripheral blood samples. Therefore, those data
were pooled for further analysis.
In vitro drug resistance assay. The
cytotoxicity of the drugs was measured by the
MTT assay. The assay conditions were essen-
tially the same as described previously [7].
Briefly, 80 l of the cell suspension containing
2 106 vital cells/ml was incubated with each
drug concentration (drug was added as a solu-
tion in 20 l RPMI) in duplicate wells of a
96-well round-bottomed microtiter plate
(Profilab, Warsaw, Poland). Six wells contain-
ing only cells in drug-free medium served as
controls for cell survival, while six other wells
containing only culture medium blanked the
spectrophotometer. The outer wells of the
plate were filled with RPMI-1640 only. Plates
were then wrapped in cling film and incubated
for 4 days (96 h) at 37C in humidified air con-
taining 5% CO2. After 4 days, 50 g (10 l of a
5 mg/ml solution) of 3-[4,5-dimethylthia-
zol-2-yl]-2,5-diphenyl tetrazolium bromide
(MTT, Serva, Heidelberg, Germany) was
added to each well (final concentration 0.45
mg/ml); plates were shaken and incubated for
another 6 h at 37C. In such an exposure yel-
low MTT was reduced to purple formazan by
viable, but not dead, cells. The formazan crys-
tals were dissolved with 100 l of acidified
(0.04 M HCl) 2-isopropanolol (Sigma,
St. Louis, MO, U.S.A.) and the quantity of the
reduced product was measured by an ELISA
EL-312 microplate spectrophotometer at
570 nm (Asys Hitech GmbH, Eugendorf, Aus-
tria). The absorbance (A570) at this wave-
length is linearly related to the number of via-
ble cells [8]. Cytospin slides from control
wells, stained with May-Grunwald-Giemsa,
were used to determine the percentage of
blasts after 96-h incubation. Samples with
more than 70% leukemic cells in the control
wells without drug after 4 days of culture and
with an A570 higher than 0.050 arbitrary units
(adjusted for blank values) were considered
suitable for evaluation. The leukemic cell sur-
vival was calculated by the equation: (A570
drug well/mean A570 control wells)  100%.
The A570 values of both control and tested
wells were adjusted by the A570 of blank wells.
The LC50 value, expressing the concentration
of the drug that was lethal to 50% of the cells,
was used as a measure of the in vitro drug
cytotoxicity in each sample.
PGP expression. PGP was analysed by flow
cytometry. Mouse monoclonal antibodies
anti-PGP-PE (cat. No. 340555, Becton
Dickinson, San Jose, CA, U.S.A.), clone 15D3
transfected with the human multidrug resis-
tance gene MDR1, were used. The amount of
PE-labelling was detected by flow cytometry;
red fluorescence was collected through a FL2
height bandpass filter set using log-mode am-
plification. Leukemic cells were gated based
on FSC and SSC characteristics, and the fluo-
rescence intensity of this population was ex-
pressed in arbitrary units on a log-scale. PGP
expression was calculated as percentage of
cells positive against isotype control of mouse
anti-IgG1-PE. No difference between the fluo-
rescence of bone marrow and peripheral blood
samples was observed, therefore those data
were pooled for further analysis.
Statistics. The non-parametric Wilcoxon
matched-pairs signed ranks test was used to
compare LC50 values for PB and BM samples.
The Mann-Whitney U test was used to com-
pare accumulation and retention rates, as well
as drug resistance, between groups. Correla-
tions between parameters were calculated
with Spearman’s rho coefficient. All tests
were used for two-tailed testing at a level of
significance of 0.05.
RESULTS
The results (intracellular concentration,
PGP expression, cytotoxicity) showed large
interpatient variability. There was a big over-
lap of results inside each group of patients.
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The uptake and efflux rates were higher for
IDA, however, the differences were not signif-
icant. There were no statistical differences
within any of the three groups of patients with
respect to drug content during accumulation
and retention (Fig. 2). It seems that the higher
rate of IDA transport was related to the
lipophilic properties of the drugs rather than
to the type of leukemia.
However, when the cell volume was used to
calculate the intracellular drug concentration
based on its intracellular content, differences
were found. Intracellular concentration of
each of the two drugs at each time point of
both uptake and efflux (Table 1, Fig. 3) was
significantly lower in relapsed ALL (group B)
and AML (group C) samples than in initial
ALL cells (group A). Those differences were
related to the cell volumes larger in groups B
and C than A (Table 2).
There was no correlation between both drug
accumulation and PGP expression at any time
point during uptake. There was an inverse
correlation between intracellular concentra-
tion of both drugs during efflux and PGP ex-
pression almost at each time point for all 61
patients (but not in any smaller group of pa-
tients with specific type of the disease) (Ta-
ble 3). The in vitro cytotoxicity expressed as
LC50 was correlated with drug retention for
IDA (p = 0.012 after 1 h and p = 0.024 after
2 h) but not DNR. The correlation between
LC50 and intracellular concentration during
accumulation showed weak significance for
both drugs (p < 0.05). The LC50 values for
DNR and IDA did not differ, whether in the
whole group of patients (median
0.3594 g/ml vs 0.3596 g/ml) or in any sub-
group, however, for each drug differences
were observed between the three types of leu-
kemia (Table 4).
DISCUSSION
Anthracyclines are among the most com-
monly used anti-tumor drugs ever developed.
The first identified anthracyclines,
daunorubicin and doxorubicin, were isolated
from pigment-producing Streptomyces species
in the early 1960s [9]. The 4-demethoxy deriv-
ative of daunorubicin, idarubicin, is more ef-
fective than the parent compound in HL60
cell line [10]. Resistance to DNR has been
shown to correlate with the prognosis of pedi-
atric patients with ALL [11]. The present
study tested whether decreased cellular up-
take or increased cellular efflux of DNR and
IDA may be responsible for cellular DNR/IDA
resistance in childhood ALL and AML. The
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Figure 2. Rate of accumulation (A) and retention
(B) of IDA and DNR in iALL, rALL and iAML cell
samples.
Cells were incubated with each drug at of 10 g/ml. The
intracellular drug content at each time point is given as
the percentage of respective value at the end (accumula-
tion phase) or at the beginning of the experiment (re-
tention phase).
A
B
intracellular anthracycline levels may be low-
ered by efflux-mediating proteins, such as
PGP, MRP and MVP/LRP [6, 12], but it is
thought that the role of these proteins in child-
hood leukemia is limited [13]. Previously, it
has been shown that the transport rate de-
pends on the hydrophobicity of the drug: more
lipophilic anthracyclines such as IDA enter
the cell faster compared with the less hydro-
phobic DNR [14]. We observed that in child-
hood leukemic cells, IDA is not only accumu-
lated faster than DNR, but it is also faster se-
questered out of the cell. This may have an im-
pact on the higher IDA cytotoxicity. The accu-
mulation rates for both drugs were inversely
correlated with LC50 values, reflecting drug
sensitivity. On the other hand, faster IDA
efflux could be related to the cellular resis-
tance to this drug. Another important obser-
vation of the study is that while there were no
differences in the intracellular content of
IDA/DNR between the types of leukemia,
there were significant differences in drug con-
centration. Larger cells were more resistant
to either anthracycline. When the intra-
cellular DNR content was corrected for cell
volume, the intracellular DNR/IDA concen-
tration inversely correlated with DNR/IDA re-
sistance, both when the accumulation and re-
tention of the drug were studied. These data
show that not the decreased intracellular con-
tent but rather the decreased intracellular
concentration may be an important mecha-
nism of resistance which plays a role in the
cytotoxic effect of both anthracyclines in
childhood leukemia. Those observations, to-
gether with earlier results [6], allowed us to
draw more general conclusions. The highest
concentration of each drug was in iALL, in
correlation with the lowest drug resistance
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Table 1. Intracellular concentration of DNR and IDA during uptake and efflux
Intracellular DNR concentration Intracellular IDA concentration
Time [h] 1 2 3 1 2 3
Uptake
iALL 19 19 19 22 21 20
rALL 11* 11** 12** 12* 13* 14
iAML 6*** 6.4*** 6*** 8.7*** 8** 8.1***
Efflux
iALL 12 8.3 6.5 14 9.1 5.7
rALL 7.6** 4.0** 3.4*** 9* 5.5** 3***
iAML 3.7*** 2.7*** 2.2*** 5.6*** 3.1*** 2.6***
The values of drug concentration are given as median concentration (AU/FSC
3
) 10
7
. Significance: P < 0.05, **P < 0.01, ***P <
0.001 in relation to iALL.
Table 2. Median cell volume and relative resistance of rALL and iAML vs iALL
Group Cell volume (FSC
3
) RR p
iALL 3.1 x 10
–7
– –
rALL 4.4 x 10
–7
1.4* 0.006
iAML 11.0 x 10
–7
3.5** <0.001
RR, relative resistance in comparison to iALL; (*) RR is the median LC50 for rALL divided by the median LC50 for iALL; (**) RR
is the median LC50 for iAML divided by the median LC50 for iALL; RR > 1 indicates that for a given drug, rALL (iAML) is more re-
sistant than iALL; p, Mann-Whitney U test.
and the best clinical results of therapy. The
intracellular DNR/IDA concentration was
much lower in rALL and iAML, in correlation
with higher drug resistance and much worse
results of anti-leukemic therapy in the pediat-
ric clinic. Finally, we observed that PGP ex-
pression may be one of the factors influencing
intracellular concentration of drugs and
cytotoxicity profile. PGP correlated with the
intracellular DNR/IDA concentration during
efflux. This is probably due to the physiologi-
cal role of PGP, which helps to sequestrate
drugs outside the cells during efflux but
rather cannot influence the intracellular drug
concentration during accumulation, since the
drug uptake is more dependent on passive
drug diffusion. It could also have a certain ef-
fect on IDA retention (as IDA was faster se-
questrated out of the cells), however, this ef-
fect can have only minor clinical significance,
since IDA caused very fast cell death. We fre-
quently observed that after 3 h of accumula-
tion most cells were killed by IDA at a concen-
tration of 10 g/ml.
In conclusion, while the intracellular content
of both anthracyclines was similar during up-
take and efflux in all groups of patients, the
intracellular concentration of the drugs was
significantly decreased in AML and relapsed
ALL children. This possibly indicates an im-
portant drug resistance mechanism in child-
hood acute leukemia. Retention of both drugs
weakly correlated with PGP expression and
IDA, but not DNR, cytotoxicity. These obser-
vations suggest higher IDA cytotoxicity, possi-
bly decreased by the presence of PGP. These
results might have a practical impact on the
rational design of new chemotherapy proto-
cols. On the other hand, anthracycline accu-
mulation can possibly be decreased also due
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Figure 3. Intracellular concentration of IDA and
DNR in iALL, rALL and iAML samples after 3 h of
uptake (A) and efflux (B).
Table 3. Correlation between intracellular drug concentration changes during efflux and PGP expres-
sion for all patients*
Time points
Intracellular DNR concentration Intracellular IDA concentration
rho p rho p
1 h –0.342 0.025 –0.377 0.013
2 h –0.388 0.012 –0.369 0.018
3 h –0.348 0.022 –0.238 0.124
*No correlations were found within any leukemia subgroup; rho, Spearman’s coefficient of correlation; p, Mann-Whitney U test.
A
B
to the presence of other drug resistance pro-
teins, such as Multidrug-Resistance Related
Protein (MRP) or Lung-Resistance-Protein
(MVP/LRP) [1].
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